Local study shows potential benefits of Xolair in treating asthma patients

Published: 2009-05-22 06:58:00

Updated: 2009-05-22 06:58:00

Interim data presented recently at the joint congress that Xolair (omalizumab) for Subcutaneous Use significantly reduced asthma attacks in 23 Korean patients with moderate or severe persistent allergic asthma inadequately controlled with inhaled corticosteroids. The study further defines the saf...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK